229 related articles for article (PubMed ID: 37658605)
1. Intratumoral CD103
Ren S; Lan T; Wu F; Chen S; Jiang X; Huo C; Li Z; Xie S; Wu D; Wang R; Li Y; Qiu L; Huang G; Li S; Wang X; Cen M; Cai T; Lin Z; Li J; Li B
Cancer Commun (Lond); 2023 Oct; 43(10):1143-1163. PubMed ID: 37658605
[TBL] [Abstract][Full Text] [Related]
2. [CD103
Li BW; Ren SQ; Chen SL; Lan TJ; Wu F; Li JS
Zhonghua Kou Qiang Yi Xue Za Zhi; 2023 Dec; 58(12):1257-1264. PubMed ID: 38061868
[No Abstract] [Full Text] [Related]
3. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
4. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira G; Egloff AM; Afeyan AB; Wolff JO; Zeng Z; Chernock RD; Zhou L; Messier C; Lizotte P; Pfaff KL; Stromhaug K; Penter L; Haddad RI; Hanna GJ; Schoenfeld JD; Goguen LA; Annino DJ; Jo V; Oppelt P; Pipkorn P; Jackson R; Puram SV; Paniello RC; Rich JT; Webb J; Zevallos JP; Mansour M; Fu J; Dunn GP; Rodig SJ; Ley J; Morris LGT; Dunn L; Paweletz CP; Kallogjeri D; Piccirillo JF; Adkins DR; Wu CJ; Uppaluri R
Sci Immunol; 2023 Sep; 8(87):eadf4968. PubMed ID: 37683037
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD103
Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
[TBL] [Abstract][Full Text] [Related]
6. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
Mann JE; Smith JD; Birkeland AC; Bellile E; Swiecicki P; Mierzwa M; Chinn SB; Shuman AG; Malloy KM; Casper KA; McLean SA; Moyer JS; Wolf GT; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
Cancer Immunol Immunother; 2019 Feb; 68(2):213-220. PubMed ID: 30361882
[TBL] [Abstract][Full Text] [Related]
7. Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy.
Choi S; Hossain M; Lee H; Baek J; Park HS; Lim CL; Han D; Park T; Kim JH; Gong G; Kweon MN; Lee HJ
Cancer Immunol Immunother; 2024 Apr; 73(6):101. PubMed ID: 38630265
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
9. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of CD103
Smith JD; Bellile EL; Ellsperman SE; Heft-Neal ME; Mann JE; Birkeland AC; Hoesli RC; Swiecicki PL; Worden FP; Schonewolf C; Shah JL; Mierzwa ML; Rosko AJ; Stucken CL; Chinn SB; Shuman AG; Casper KA; Malloy KM; Prince MEP; Wolf GT; Thomas DG; McHugh JB; Chad Brenner J; Spector ME
Oral Oncol; 2022 Dec; 135():106226. PubMed ID: 36323071
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R; Ballesteros-Merino C; Frye AK; Tran E; Rajamanickam V; Chang SC; Koguchi Y; Bifulco CB; Bernard B; Leidner RS; Curti BD; Fox BA; Urba WJ; Bell RB; Weinberg AD
Nat Commun; 2021 Feb; 12(1):1047. PubMed ID: 33594075
[TBL] [Abstract][Full Text] [Related]
14. CD103
Xiao Y; Li H; Mao L; Yang QC; Fu LQ; Wu CC; Liu B; Sun ZJ
J Dent Res; 2019 Dec; 98(13):1480-1487. PubMed ID: 31658426
[TBL] [Abstract][Full Text] [Related]
15. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
[TBL] [Abstract][Full Text] [Related]
16. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive profile of TCF1
Wang D; Fang J; Wen S; Li Q; Wang J; Yang L; Dai W; Lu H; Guo J; Shan Z; Xie W; Liu X; Wen L; Shen J; Wang A; Chen Q; Wang Z
Int J Oral Sci; 2022 Feb; 14(1):8. PubMed ID: 35153298
[TBL] [Abstract][Full Text] [Related]
18. CD103
Chu Y; Liao J; Li J; Wang Y; Yu X; Wang J; Xu X; Xu L; Zheng L; Xu J; Li L
J Cancer; 2019; 10(21):5234-5243. PubMed ID: 31602274
[TBL] [Abstract][Full Text] [Related]
19. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
20. Fewer tumour-specific PD-1
Xu K; Fu Y; Han Y; Xia R; Xu S; Duan S; Zhang Z; Li J
Br J Cancer; 2020 Sep; 123(6):932-941. PubMed ID: 32616847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
